Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
26-28 August, 2025
APGA Annual ConferenceAPGA Annual Conference
Not Confirmed
Not Confirmed
20-23 July, 2025
Not Confirmed
Not Confirmed
24-25 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
26-28 August, 2025
APGA Annual ConferenceAPGA Annual Conference
Industry Trade Show
Not Confirmed
20-23 July, 2025
Industry Trade Show
Not Confirmed
24-25 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
10 Jul 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250710074037/en/Mirum-Pharmaceuticals-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4
10 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250610559917/en/Mirum-Pharmaceuticals-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4
19 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250519899640/en/Mirum-Pharmaceuticals-Appoints-Doug-Sheehy-JD-as-Chief-Legal-Officer
14 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250514147482/en/Mirum-Pharmaceuticals-to-Participate-in-Upcoming-Investor-Conferences
09 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250509189818/en/Volixibat-Data-from-Mirums-VANTAGE-PBC-Study-Showcased-at-EASL
09 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250509671797/en/Mirum-Pharmaceuticals-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4
ABOUT THIS PAGE